deutetrabenazine

Ligand id: 8707

Name: deutetrabenazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 38.77
Molecular weight 317.2
XLogP 2.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoj√§rvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP et al.. (2017)
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Psychiatry4 (8): 595-604. [PMID:28668671]
2. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D. (2017)
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
J Clin Mov Disord4: 3. [PMID:28265459]
3. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS et al.. (2017)
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
Neurology88 (21): 2003-2010. [PMID:28446646]
4. Gant TG. (2014)
Using deuterium in drug discovery: leaving the label in the drug.
J. Med. Chem.57 (9): 3595-611. [PMID:24294889]
5. Geschwind MD, Paras N. (2016)
Deutetrabenazine for Treatment of Chorea in Huntington Disease.
JAMA316 (1): 33-5. [PMID:27380339]
6. Huntington Study Group. (2006)
Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial.
Neurology66 (3): 366-72. [PMID:16476934]
7. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D et al.. (2016)
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
JAMA316 (1): 40-50. [PMID:27380342]